Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Israpafant is a selective antagonist for the platelet-activating factor receptor ( IC50 = 0.84nM). Israpafant inhibits PAF-induced human platelet aggregation. Israpafant inhibits the activation of eosinophil cells and consequently delays the development of immune responses. Israpafant also has anti-nephrotoxic properties and to mobilize calcium transport.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,420.00 | |
50 mg | 10-14 weeks | $ 3,180.00 | |
100 mg | 10-14 weeks | $ 4,300.00 |
Description | Israpafant is a selective antagonist for the platelet-activating factor receptor ( IC50 = 0.84nM). Israpafant inhibits PAF-induced human platelet aggregation. Israpafant inhibits the activation of eosinophil cells and consequently delays the development of immune responses. Israpafant also has anti-nephrotoxic properties and to mobilize calcium transport. |
Synonyms | Y-24180, Y 24180, Y24180 |
Molecular Weight | 489.07 |
Formula | C28H29ClN4S |
CAS No. | 117279-73-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Israpafant 117279-73-9 Y-24180 Y 24180 Y24180 inhibitor inhibit